Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program, including the extended half-life cytokine DF6002 as a potential treatment for solid and hematological cancers.
Business updates for various pharma and life science companies around the globe.
The U.S. FDA approved Janssen’s Xarelto (rivaroxaban) for preventing blood clots in acutely sick patients in hospitals who are at risk for blood clots but who are not at high risk of bleeding.
Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.
Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.
AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint.
Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).
Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.
Paris-based Sanofi has acquired Waltham, Mass.-based Bioverativ for about $11.6 billion.
Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.